Synaptogenix, Inc. (SNPX)
NASDAQ: SNPX · Real-Time Price · USD
2.675
+0.160 (6.36%)
At close: Jun 2, 2025, 4:00 PM
2.740
+0.065 (2.43%)
After-hours: Jun 2, 2025, 7:41 PM EDT
Synaptogenix Employees
Synaptogenix had 4 employees as of December 31, 2024. The number of employees decreased by 1 or -20.00% compared to the previous year.
Employees
4
Change (1Y)
-1
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$3,241,366
Market Cap
3.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | -1 | -20.00% |
| Dec 31, 2023 | 5 | 0 | - |
| Dec 31, 2022 | 5 | 1 | 25.00% |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SNPX News
- 5 months ago - Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - PRNewsWire
- 9 months ago - Synaptogenix Announces $5.0 Million Financing - PRNewsWire
- 11 months ago - Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - PRNewsWire
- 1 year ago - Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - PRNewsWire
- 1 year ago - Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery - PRNewsWire
- 1 year ago - Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - PRNewsWire
- 1 year ago - Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing - PRNewsWire
- 1 year ago - Synaptogenix President Daniel L. Alkon, M.D. - PRNewsWire